EBS a biotech company focused on vaccinesEBS is a small biotechnology company whose forte is the clean processing and manufacturing
facility that the FDA requires for certain bioprocessing to be certified for delivery of products
to end-user patients. It is not a research facility like the one in China that accidentally released
COVID and the global impact will be likely felt for another decade. EBS does depend on
federal support and income from contract work from vaccine manufacturers. There is
reasonable expectation or persistent and consistent revenues ongoing without fail unless
the FDA decertified the facilities. On the chart, EBS is in a flat bottom triangle on its base.
It is presently rising out of the triangle and towards the mean anchored VWAP It is just above
The POC line which functions as dynamic support in the demand zone. I see a long trade
with the stop loss below the POC line, the first target the blue line representing one standard
deviation above the mean VWAP at about 9.4 while the second target is the redline two
standard deviations above the mean VWAP at about 10.05 while the final target contemplates
that EBS will challenge the high in May of 10.75.
